MEGGLE brings advanced DPI and co-processed lactose to FCE Pharma Brazil

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) will attend Brazil’s big FCE Pharma expo in São Paulo as an exhibitor.

Once again, MEGGLE will exhibit in partnership with its Brazilian exclusive distributor, Evonik Brasil.

Lactose products and excipients

MEGGLE will use the event to showcase its latest range of lactose-based excipients and services, with particular emphasis on its new generation dry powder inhalation (DPI) and co-processed excipients.

Stars of the MEGGLE display will include the InhaLac® range of sieved, milled and micronized DPI lactose powder excipients, along with Cellactose®80, MicroceLac®100, StarLac®, RetaLac® and CombiLac® lactose-based co-processed excipients.

“Not only is this one of Latin America’s foremost pharmaceutical networking events but also presents us with a great stage from which to display our unrivalled range of lactose-based products and excipients,” said Fábio Luis Ikuno, Managing Director of MEGGLE Latin America, who will lead the team at FCE Pharma.

Web-based configuration

MEGGLE will also use its stand display to introduce end-users to its recently developed web-based Product Configurator that allows customers to identify the correct product by basic applications and characteristics. (See link below).

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About FCE Pharma 2018

The FCE Pharma Expo is an annual event that has become a principal marketing, communications and sales platform for the pharmaceutical industry in Latin America. The 23rd FCE Pharma Expo (FCE Brasil 2018) will again be a three-day event opening on May 22 at the São Paulo Expo center in , Brazil.

The 2017 event attracted more than 19,000 visitors and some 500 exhibitors, representing a host of pharmaceutical industry professionals connected with manufacture, supply and distribution of products and services including packaging, labeling, machines and equipment, quality and contamination control, transport and logistics, outsourcing and consultancy, laboratory and analytical equipment, process equipment, valves, sprays, industrial automation, technology and printing services.

The event is organized by Nürnberg Messe Brazil with more information at http://www.fcepharma.com.br/en/.